Takashi Kamimura

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 4

Forward Citations = 46(Granted Patents)

Location History:

Hino, JP (1992 - 2002)
Tokyo, JP (1989 - 2009)

Company Filing History:

Meiji Seika Kaisha, Ltd.

patents

1 out of 1

Veritas in Silico Inc.

patent

Years Active: 1989-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435358 - Method for screening compound for controlling RNA function (2025-10-07),

2. 7576117 - Cyclic amine CCR3 antagonist (2009-08-18),

3. 7390830 - Remedies or prophylactics for diseases in association with chemokines (2008-06-24),

4. 6432978 - SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities (2002-08-13),

5. 5851983 - Elastase inhibitory polypeptide and process for production thereof by (1998-12-22),

6. 5808144 - Benzene derivatives (1998-09-15),

7. 5153308 - S-sulfonated calcitonin derivatives (1992-10-06),

8. 5116942 - Protein having an inflammatory phospholipase A.sub.2 inhibitory activity (1992-05-26),

9. 4965350 - Pyridopyrimidine nucleotide compounds (1990-10-23),

10. 4810780 - Protein having phospholipase A2 inhibitory activity (1989-03-07),

Title: Takashi Kamimura: Innovator in RNA Function and Medicine

Introduction

Takashi Kamimura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the fields of RNA function and medicinal chemistry. With a total of 10 patents, his work has had a considerable impact on both scientific research and practical applications.

Latest Patents

One of Kamimura's latest patents is a method for screening compounds for controlling RNA function. This innovative method involves calculating the existence probability of a local secondary structure that may exist in a target RNA sequence. It includes selecting a local secondary structure with the desired existence probability, preparing a screening probe corresponding to the selected structure, and screening for the compound using the probe. Another notable patent is for a cyclic amine CCR3 antagonist. This medicine contains a cyclic amine derivative as an active ingredient and is designed to treat or prevent diseases in which CCR3 participates, such as asthma and allergic rhinitis.

Career Highlights

Throughout his career, Kamimura has worked with several notable companies, including Teijin Limited and Meiji Seika Kaisha, Ltd. His expertise in the field has allowed him to develop innovative solutions that address pressing medical challenges.

Collaborations

Kamimura has collaborated with esteemed colleagues, including Kenichi Masuda and Masahiro Okada. These partnerships have further enhanced his research and development efforts.

Conclusion

Takashi Kamimura is a distinguished inventor whose work in RNA function and medicinal chemistry continues to influence the scientific community. His innovative patents and collaborations reflect his commitment to advancing technology and improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.